These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. COX-2 selective inhibitors and heart health. Simon LS; White WB Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717 [TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis of VIOXX in Australia: using clinical trial data and linked administrative health data to predict patient groups at risk of an adverse drug event. Whitstock MT; Pearce CM; Ridout SC; Eckermann EJ Aust N Z J Public Health; 2010 Aug; 34(4):431-2. PubMed ID: 20649787 [No Abstract] [Full Text] [Related]
24. Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research. Berger E Ann Emerg Med; 2008 Aug; 52(2):137-9. PubMed ID: 18672488 [No Abstract] [Full Text] [Related]
26. [How many harmed by rofecoxib in Germany?]. Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670 [No Abstract] [Full Text] [Related]
27. Merck's Careful Study of Vioxx. Mayer TV Am J Cardiol; 2008 Apr; 101(7):1068-9; author reply 1069. PubMed ID: 18359336 [No Abstract] [Full Text] [Related]
28. Observational studies and the withdrawal of rofecoxib. Watson DJ; Santanello NC Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998 [No Abstract] [Full Text] [Related]
29. Reply to the Vioxx debacle. Knudsen JF; Sokol GH Am J Med; 2006 Jan; 119(1):93-4. PubMed ID: 16431207 [No Abstract] [Full Text] [Related]
30. [Rofecoxib increases myocardial infarction risk in seniors]. Wasielewski S Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032 [No Abstract] [Full Text] [Related]
31. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry. Cahana A; Mauron A J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707 [No Abstract] [Full Text] [Related]
32. The withdrawal of rofecoxib. Arellano FM Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267 [No Abstract] [Full Text] [Related]
34. A message from the Vioxx case. Baldwin HJ; Droege M; Daniel KL Am J Health Syst Pharm; 2006 Mar; 63(6):503. PubMed ID: 16522877 [No Abstract] [Full Text] [Related]
35. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? Lynch PM Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962 [No Abstract] [Full Text] [Related]
36. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib]. Mühlbauer B; Timm J Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669 [No Abstract] [Full Text] [Related]
37. The NSAID roller coaster: more about rofecoxib. Aronson JK Br J Clin Pharmacol; 2006 Sep; 62(3):257-9. PubMed ID: 16934039 [No Abstract] [Full Text] [Related]
38. Dispute over Vioxx study plays out in New England journal. Kondro W CMAJ; 2006 May; 174(10):1397. PubMed ID: 16682702 [No Abstract] [Full Text] [Related]
39. Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs. Ravaud P; Tubach F Joint Bone Spine; 2005 Dec; 72(6):451-5. PubMed ID: 16330235 [TBL] [Abstract][Full Text] [Related]